November 2, 2017 (NEW YORK) – Proskauer represented long-time client Celgene Corporation in the successful pricing of three series of senior unsecured notes for an aggregate principal amount of $3 billion. Of these notes, $750 million will mature in 2023, $1 billion will mature in 2027 and $1.25 billion will mature in 2047. The 2.750 percent notes due 2023, the 3.450 percent notes due 2027 and the 4.350 percent notes due in 2047 were priced to yield 2.762 percent, 3.468 percent and 4.366 percent, respectively.  

Barclays Capital Inc., Credit Suisse Securities (USA) LLC, Goldman Sachs & Co. LLC, J.P. Morgan Securities LLC and Morgan Stanley & Co. LLC are acting as joint book-running managers and representatives of the several underwriters.

Proskauer has represented Celgene, one of the world’s largest biopharmaceutical companies, in all of its capital markets transactions since the company’s inception in 1986.

The Proskauer team was led by partners Frank Lopez and Steven Gruberg (Capital Markets); partner Robert Cantone; and associates Caitlin O’Hern and William Majeski (Corporate).